Our process isolates single B cells and validates the function of their secreted antibodies to screen for high-affinity and high-specificity candidates. We then perform sequencing and bioinformatics analysis to create a one-to-one map between antibody sequence and function, enabling the precise identification of desired antibody sequences. Each microwell in our OptoBot® 1000 or its series products is 100,000 times smaller than a well in a standard 384-well plate. The OptoBot® 1000 or its series products supports long-term cell culture through automated medium exchange, shortening the antibody development cycle by up to two months.